AstraZeneca, in conjunction with Alexion, will unveil a breadth of data spanning 63 abstracts at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. These data, incorporating 14 approved and potential new medicines, including rare disease group Alexion’s contributions, will encompass chronic lymphocytic leukemia (CLL), various lymphoma types, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uraemic syndrome (aHUS), and amyloid light-chain (AL) amyloidosis.
Advancing Hematology: AstraZeneca’s Breakthroughs at ASH 2023
Anas Younes, AstraZeneca’s Senior Vice President of Hematology R&D, highlighted the company’s pioneering advancements in hematology through multiple innovative modalities. The unveiling of updated clinical data for AZD0486, a CD19/CD3 T-cell engager, reaffirms its potential as a novel lymphoma treatment. Additionally, new Calquence data from the ELEVATE-TN Phase III trial underpin the drug’s extended efficacy, safety, and tolerability over six years in treatment-naïve CLL patients.
Further, AstraZeneca will present findings from their early pipeline, showcasing a range of scientific platforms such as Immuno-Oncology, Immune-Engagers, Antibody Drug Conjugates (ADCs), and Epigenetics. Noteworthy highlights include promising Phase I results for AZD0486 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and the debut of sabestomig, a PD-1/TIM-3 targeting bispecific antibody, exhibiting initial signs of efficacy in R/R Hodgkin lymphoma.
ALPHA Trial Highlights at ASH 2023
A pivotal focus lies on Factor D inhibition’s potential impact on paroxysmal nocturnal hemoglobinuria (PNH) patients experiencing clinically significant extravascular hemolysis (EVH) while on C5 inhibitor therapy. The ALPHA Phase III trial’s new results will reveal danicopan’s potential as an add-on therapy, enabling patients to sustain intravascular hemolysis (IVH) control through standard-of-care treatment with Ultomiris or Soliris.
Moreover, real-world analyses across various rare hematological conditions, such as AL amyloidosis, aHUS, and hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), aim to augment scientific comprehension and enhance management strategies for these life-threatening diseases.
Resoruce: AstraZeneca, November 29, 2023
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
